A Delaware court recently dismissed a derivative lawsuit against Illumina, Inc., a biotechnology company, concerning its controversial merger with GRAIL, Inc. The lawsuit, filed by stockholders, alleged that Illumina's board of directors breached their fiduciary duties by proceeding with the merger despite potential violations of antitrust laws and European Union regulations. The court's ruling has significant implications for Illumina's shareholders and corporate governance practices.

The case, known as In re Illumina, Inc. Consolidated Derivative Stockholder Litigation (C.A. No. 2024-1337-PAF), was decided on October 30, 2026. The plaintiffs in the case argued that the board's actions could expose them to personal liability, and therefore, they claimed that a demand for the board to take action would have been futile. The court's decision to dismiss the case means that the plaintiffs will not be able to hold the board accountable for their decisions regarding the merger.

Background

Illumina, Inc. is a Delaware corporation that specializes in next-generation sequencing (NGS) technology, which is crucial for genetic and genomic analysis. The company had previously acquired GRAIL, Inc., a subsidiary focused on developing multi-cancer early detection tests. In 2021, Illumina attempted to reacquire GRAIL after it had spun off in 2017. The merger was valued at $8.3 billion and was met with scrutiny from regulators, particularly concerning antitrust laws.

The plaintiffs, represented by various law firms including Scott+Scott Attorneys at Law LLP and Grant & Eisenhofer P.A., claimed that the Illumina board acted recklessly by not adequately addressing potential legal violations associated with the merger. They argued that the board's actions could lead to personal liability under Delaware law, specifically citing the precedent set in In re Massey Energy Co.

The Ruling

The court ruled in favor of the defendants, granting their motion to dismiss the complaint. The ruling stated, "The plaintiffs have failed to demonstrate that demand on the Illumina board of directors is excused." The court found that the plaintiffs did not adequately plead demand futility, which is a legal standard that allows shareholders to bypass the requirement of asking the board to take action before filing a lawsuit.

The court emphasized that the allegations did not sufficiently show that a majority of the directors faced a substantial likelihood of personal liability. The ruling underscored the importance of the board's discretion in corporate governance and the challenges faced by shareholders in proving demand futility.

Impact

This ruling has significant implications for Illumina and its shareholders. By dismissing the lawsuit, the court reinforced the ability of corporate boards to make strategic decisions without the immediate threat of litigation from shareholders. This decision may also discourage similar derivative actions against corporate boards in the future, particularly in cases involving complex mergers and acquisitions.

Moreover, the ruling highlights the challenges that shareholders face in holding directors accountable for their decisions. It sets a precedent that may make it more difficult for shareholders to successfully argue demand futility in derivative lawsuits, potentially limiting their ability to challenge corporate governance practices.

What's Next

The plaintiffs have the option to appeal the court's decision, but it remains to be seen whether they will pursue that route. Additionally, there may be ongoing regulatory scrutiny regarding the merger between Illumina and GRAIL, as the implications of the merger continue to unfold in the public and legal arenas.